364 results
Page 11 of 19
8-K
EX-99.1
v8mzw
4 Mar 11
Bristol-Myers Squibb Names Elliott Sigal, M.D., Ph.D., to
12:00am
8-K
EX-99.1
21jxcrjamrs 57aiw380
27 Jan 11
Receives U.S. Regulatory Approval for KOMBIGLYZE™ XR, and First-Line Indication for SPRYCEL® in Fourth Quarter
12:00am
8-K
EX-99.1
a3qfmsv1
9 Nov 10
Bristol-Myers Squibb Announces Cash Tender Offer For Up to $750 Million
12:00am
8-K
EX-99.1
v7hj1ralxd8owl yzoo
26 Oct 10
Robust Clinical Data and the Strategic Acquisition of ZymoGenetics
12:00am
8-K
EX-99.1
mi6es4sm c6qjtdtsc
12 Oct 10
Other Events
12:00am
SC TO-T/A
EX-99
81dfaf 5sh
13 Sep 10
Third party tender offer statement (amended)
12:00am
8-K
EX-99.1
016d6n2tfy0 8iph
10 Sep 10
Bristol-Myers Squibb to Acquire ZymoGenetics
12:00am
SC TO-C
scs4sw5kfruy8qupgu
7 Sep 10
Information about tender offer
12:00am
8-K
EX-99.1
lltq s4u4zauuiia
22 Jul 10
Bristol-Myers Squibb Second Quarter Featured Robust Clinical Data
12:00am
8-K
EX-99.1
39kqcqjfs3ebc fxwg9o
24 Dec 09
Bristol-Myers Squibb and Mead Johnson Announce
12:00am
425
9ume9
23 Dec 09
Business combination disclosure
12:00am
425
yhnsrp0xj8 j33
23 Dec 09
Business combination disclosure
12:00am